Ventyx Biosciences Stock Today
| VTYX Stock | USD 1.71 0.03 1.79% |
PerformanceWeak
| Odds Of DistressAverage
|
Ventyx Biosciences is trading at 1.71 as of the 16th of February 2025; that is 1.79 percent increase since the beginning of the trading day. The stock's open price was 1.68. Ventyx Biosciences has 51 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 18th of November 2024 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of October 2021 | Category Healthcare | Classification Health Care |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California. Ventyx Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 70.71 M outstanding shares of which 6.37 M shares are at this time shorted by private and institutional investors with about 3.4 trading days to cover. More on Ventyx Biosciences
Moving together with Ventyx Stock
Moving against Ventyx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ventyx Stock Highlights
| CEO, Founder | Raju Mohan | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVentyx Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ventyx Biosciences' financial leverage. It provides some insight into what part of Ventyx Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Ventyx Biosciences (VTYX) is traded on NASDAQ Exchange in USA. It is located in 12790 El Camino Real, San Diego, CA, United States, 92130 and employs 75 people. Ventyx Biosciences is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 120.92 M. Ventyx Biosciences conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 70.71 M outstanding shares of which 6.37 M shares are at this time shorted by private and institutional investors with about 3.4 trading days to cover.
Ventyx Biosciences currently holds about 250.45 M in cash with (166.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Ventyx Biosciences Probability Of Bankruptcy
Ownership AllocationVentyx Biosciences shows a total of 70.71 Million outstanding shares. The majority of Ventyx Biosciences outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Ventyx Biosciences to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Ventyx Biosciences. Please pay attention to any change in the institutional holdings of Ventyx Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Ventyx Ownership Details
Ventyx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Vestal Point Capital Lp | 2024-09-30 | 1.7 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.4 M | |
| Ubs Group Ag | 2024-09-30 | 1.2 M | |
| State Street Corp | 2024-09-30 | 1.2 M | |
| Sphera Funds Management Ltd. | 2024-09-30 | 1 M | |
| Bank Of America Corp | 2024-09-30 | 897 K | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 568.5 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 488.7 K | |
| Northern Trust Corp | 2024-09-30 | 465.7 K | |
| Deerfield Management Co | 2024-09-30 | 6.7 M | |
| Blackrock Inc | 2024-09-30 | 4.9 M |
Ventyx Biosciences Historical Income Statement
Ventyx Stock Against Markets
Ventyx Biosciences Corporate Management
| Matthew Moore | Chief Officer | Profile | |
| Snehal Naik | Senior Development | Profile | |
| Kye MD | Data Biostatistics | Profile | |
| Sheila MD | Executive Chairperson | Profile | |
| John Nuss | Chief Officer | Profile | |
| Martin MD | Chief Officer | Profile | |
| Kathy Ogilvie | Senior Research | Profile |
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.